Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on These Healthcare Stocks: Viatris (VTRS), Scholar Rock Holding (SRRK)

Tipranks - Tipranks - Sat Mar 21, 7:18AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viatris (VTRS), Scholar Rock Holding (SRRK) and Fortrea Holdings Inc. (FTRE) with bullish sentiments.

Claim 70% Off TipRanks Premium

Viatris (VTRS)

Truist Financial analyst Les Sulewski maintained a Buy rating on Viatris today. The company’s shares closed last Thursday at $13.50, close to its 52-week high of $13.55.

According to TipRanks.com, Sulewski is a 3-star analyst with an average return of 2.1% and a 43.1% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Bausch Health Companies, and Amneal Pharmaceuticals. ;'>

Currently, the analyst consensus on Viatris is a Moderate Buy with an average price target of $14.80.

See Insiders’ Hot Stocks on TipRanks >>

Scholar Rock Holding (SRRK)

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Scholar Rock Holding. The company’s shares closed last Thursday at $45.50, close to its 52-week high of $46.98.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 15.1% and a 51.9% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Protagonist Therapeutics, and Madrigal Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Scholar Rock Holding with a $56.67 average price target, representing a 44.8% upside. In a report issued on March 5, TipRanks – Google also upgraded the stock to Buy with a $53.00 price target.

Fortrea Holdings Inc. (FTRE)

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Fortrea Holdings Inc.. The company’s shares closed last Thursday at $9.79, close to its 52-week low of $8.00.

According to TipRanks.com, Singh is ranked 0 out of 5 stars with an average return of -16.4% and a 29.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Revolution Medicines, and Privia Health Group. ;'>

Currently, the analyst consensus on Fortrea Holdings Inc. is a Moderate Buy with an average price target of $15.86, representing a 63.2% upside. In a report issued on March 6, TD Cowen also upgraded the stock to Buy with a $15.00 price target.

Read More on VTRS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).